- Home
- PETS vs ALGS Comparison
PETS vs ALGS Comparison
Compare PETS & ALGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PETS
- ALGS
- Stock Information
- Founded
- PETS 1996
- ALGS 2018
- Country
- PETS United States
- ALGS United States
- Employees
- PETS N/A
- ALGS N/A
- Industry
- PETS Retail-Drug Stores and Proprietary Stores
- ALGS Biotechnology: Pharmaceutical Preparations
- Sector
- PETS Consumer Staples
- ALGS Health Care
- Exchange
- PETS Nasdaq
- ALGS Nasdaq
- Market Cap
- PETS 57.8M
- ALGS 64.8M
- IPO Year
- PETS N/A
- ALGS 2020
- Fundamental
- Price
- PETS $1.99
- ALGS $6.56
- Analyst Decision
- PETS Sell
- ALGS Strong Buy
- Analyst Count
- PETS 1
- ALGS 2
- Target Price
- PETS $3.20
- ALGS $60.00
- AVG Volume (30 Days)
- PETS 176.5K
- ALGS 81.3K
- Earning Date
- PETS 11-03-2025
- ALGS 11-06-2025
- Dividend Yield
- PETS N/A
- ALGS N/A
- EPS Growth
- PETS N/A
- ALGS N/A
- EPS
- PETS N/A
- ALGS N/A
- Revenue
- PETS $226,972,000.00
- ALGS $2,646,000.00
- Revenue This Year
- PETS N/A
- ALGS N/A
- Revenue Next Year
- PETS $2.98
- ALGS N/A
- P/E Ratio
- PETS N/A
- ALGS N/A
- Revenue Growth
- PETS N/A
- ALGS N/A
- 52 Week Low
- PETS $1.93
- ALGS $3.76
- 52 Week High
- PETS $6.85
- ALGS $46.80
- Technical
- Relative Strength Index (RSI)
- PETS 34.39
- ALGS 32.95
- Support Level
- PETS $1.93
- ALGS $6.10
- Resistance Level
- PETS $2.92
- ALGS $7.00
- Average True Range (ATR)
- PETS 0.16
- ALGS 0.74
- MACD
- PETS -0.04
- ALGS -0.16
- Stochastic Oscillator
- PETS 6.57
- ALGS 19.29
About PETS PetMed Express Inc.
PetMed Express Inc along with its subsidiaries is a nationwide pet pharmacy. The company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats, direct to the consumer. The company generates its revenue by selling pet medications and pet supplies mainly to retail consumers.
About ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.